Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bausch & Lomb

This article was originally published in The Tan Sheet

Executive Summary

Ronald Zarrella named CEO effective immediately, firm says Nov. 13. Zarrella rejoins eye care company after seven years at General Motors, most recently as exec VP/president of its North America division. He first joined B&L in 1985, rising to president/COO before leaving in 1994. He replaces William Waltrip, who temporarily assumed the post following William Carpenter's departure in September (1"The Tan Sheet" Sept. 10, p. 32)...

You may also be interested in...

Bausch & Lomb

Board chair William Waltrip also will serve as CEO, replacing William Carpenter, while board conducts external search for permanent chief exec, firm announces Sept. 4. Carpenter, who has led eye care maker since January 1997 (when he replaced Waltrip), is leaving for "personal reasons" during a time of slow contact lens, eye care business. B&L has retained Heidrick & Struggles to assist in its search

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.







Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts